

10/505,337 SEARCHER/EXAMINER YONG CHU 2-16-2006

\$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAYLC1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS	4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	6	DEC 14	CA/CAPLUS to be enhanced with updated IPC codes
NEWS	7	DEC 21	IPC search and display fields enhanced in CA/CAPLUS with the IPC reform
NEWS	8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	9	JAN 13	IPC 8 searching in IFIPAT, IFIUDb, and IFICDB
NEWS	10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	13	JAN 30	Saved answer limit increased
NEWS	14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:39:53 ON 16 FEB 2006

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:40:04 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9
DICTIONARY FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10505337\10505337.str



chain nodes :
7 8 9 10
ring nodes :
1 2 3 4 5 6
chain bonds :
3-10 6-7 7-8 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
3-10 6-7 7-8 8-9
normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:40:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6805 TO ITERATE

29.4% PROCESSED 2000 ITERATIONS

42 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 131155 TO 141045

PROJECTED ANSWERS: 2141 TO 3575

L2 42 SEA SSS SAM L1

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.88

1.09

STN INTERNATIONAL LOGOFF AT 07:41:06 ON 16 FEB 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAYLC1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:47:22 ON 16 FEB 2006

=> ile reg

ILE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY	SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:47:30 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9
DICTIONARY FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10505337\10505337a.str




chain nodes :
7 8 9 10
ring nodes :
1 2 3 4 5 6
chain bonds :
3-10 6-7 7-8 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
3-10 6-7 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
Generic attributes :
9:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:47:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6805 TO ITERATE

29.4% PROCESSED 2000 ITERATIONS 22 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 131155 TO 141045
PROJECTED ANSWERS: 978 TO 2016

L2 22 SEA SSS SAM L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	0.65

FILE 'CAPLUS' ENTERED AT 07:48:07 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 15 Feb 2006 (20060215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12 and prepar?

```
      15 L2
1616997 PREPAR?
120651 PREP
  2141 PREPS
122586 PREP
      (PREP OR PREPS)
1985242 PREPD
  21 PREPDS
1985257 PREPD
      (PREPD OR PREPDS)
116966 PREPG
  12 PREPGS
116977 PREPG
      (PREPG OR PREPGS)
2677022 PREPN
203051 PREPNS
2830331 PREPN
      (PREPN OR PREPNS)
4679865 PREPAR?
      (PREPAR? OR PREP OR PREPD OR PREPG OR PREPN)
```


L3 14 L2 AND PREPAR?

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1290198 CAPLUS
DOCUMENT NUMBER: 144:36347
TITLE: Preparation of triazoles as modulators of
peroxisome proliferator activated receptors (PPAR).
INVENTOR(S): Zhu, Yan; Ma, Jingyuan; Cheng, Peng; Zuchun;
Gregoire, Francine M.; Rakhmanova, Vera A.
PATENT ASSIGNEE(S): Metabolex, Inc., USA
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115383	A2	20051208	WO 2005-US18318	20050524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006014809 A1 20060119 US 2005-137678 20050524				
PRIORITY APPLN. INFO.: US 2004-574426P P 20040525				

GI




AB Title compds. [I: Ar1 = (substituted) Ph, naphthyl, imidazolyl, benzimidazolyl, pyrrolyl, indolyl, thienyl, benzothienyl, furyl, benzofuryl, benzodioxolyl; Ar2 = (substituted) Ph, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl; L = specified linker having 1-6 atoms; K = bond, specified linker having 1-6 chain atoms; R1 = H, halo, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; Z = CH2OR6, CO2R6, tetrazol-5-yl, CONHSO2R2, CHO; R2 = H, alkyl, haloalkyl, aryl, aralkyl, heteroaryl, etc.; R6 = H, alkyl, haloalkyl, alkenyl, cycloalkyl, heterocyclyl, aralkyl, aralkenyl, etc.; with provisoes], were prepared I are useful in treatment of type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders. Thus, 2-methyl-2-[2-methyl-4-[5-methyl-2-(4-trifluoromethylphenyl)-2H-1,2,3-triazol-4-ylmethylsulfanyl]phenoxy]propion

L3 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:638853 CAPLUS
DOCUMENT NUMBER: 143:153366
TITLE: Preparation of bicyclic derivatives as PPAR modulators
INVENTOR(S): Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guokun; Herr, Robert Jason
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066136	A1	20050721	WO 2004-US39773	20041216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: US 2003-332139P P 20031222				
US 2004-586677P P 20040709				

OTHER SOURCE(S): MARPAT 143:153366
GI





ACCESSION NUMBER: 2005:523433 CAPLUS
DOCUMENT NUMBER: 143:59963

TITLE: Preparation of isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
INVENTOR(S): Fukui, Yoshikazu; Sasatani, Takashi; Matsumura, Ken-ichi; Ishizuka, Natsuki; Yano, Toshisada; Kanda, Yasuhiko; Chomei, Nobuo
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 289 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054213	A1	20050616	WO 2004-JP17706	20041129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CM, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2003-403274 A 20031202
JP 2004-121635 A 20040416
JP 2004-167941 A 20040607
JP 2004-316251 A 20041029


OTHER SOURCE(S): MARPAT 143:59963
GI



AB Title compds. I [R1 = halo, etc.; R2 = H, halo, etc.; R3, R4 = H, halo, etc.; R5, R6, R7, R8 = H, halo, etc.; R9, R10 = H, halo, etc.; X1 = O, etc.; X2 = single bond, etc.; X3 = CO2R17, etc.; R17 = H, alkyl] were prepared. For example, hydrolysis of compound II [R = OMe], e.g., prepared from 2-(4-dimethylcarbamoylsulfanyphenyl)thiophene-3-carboxylic acid Me ester in 2 steps, afforded compound II [R = OH] in 86% yield. In PPAR δ activation assays, the EC50 value of compound II [R = OH] was 14 nM. Compds. I are claimed useful as PPAR (peroxisome proliferator-activated receptor) agonist.
IT 854009-50-OP 854010-08-SP
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoxazole derivative as peroxisome proliferator-activated receptor agonist)
RN 854009-50-0 CAPLUS
CN Acetic acid, 4-[[[4-(methoxymethyl)-5-[4-(trifluoromethyl)phenyl]-3-isoxazolyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 854010-08-5 CAPLUS
CN Acetic acid, 4-[[[4-([1,1'-biphenyl]-4-ylmethyl)-5-[4-(trifluoromethyl)phenyl]-3-isoxazolyl]methyl]thio]-2-methylphenoxy]-ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER: 2003:1006960 CAPLUS
DOCUMENT NUMBER: 140:42181

TITLE: Preparation of benzimidazolecarboxamides as poly(ADP-ribosyl) polymerase inhibitors for treatment of cancer
INVENTOR(S): Skaltitzky, Donald James; Webber, Stephen E.; Eastman, Brian Walter
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106430	A1	20031224	WO 2003-1B2344	20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004034078	A1	20040219	US 2003-453973	20030604
AU 2003233106	A1	20031231	AU 2003-233106	20030610
PRIORITY APPLN. INFO.:			US 2002-388840P	P 20020614
			WO 2003-1B2344	W 20030610

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein n = 0 or 1; R1 = H, alkyl, aryl, heteroaryl, (un)substituted heterocycloalkyl; X = S(O)m; m = 0, 1, or 2; N(R3); R3 = H, alkyl; or when n = 1, NR3R1 = (un)substituted 3- to 10-membered heterocycle; R2 = H, alkyl; or R1R2NC = (un)substituted 5- to 8-membered heterocycle]; their pharmaceutical acceptable salts, prodrugs, active metabolites and solvates] were prepared as poly(ADP-ribosyl)transferase (PARP) inhibitors for treatment of cancers, and amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, I may be used in combination with cytotoxic agents and/or radiation. For example, II was prepared via Rink amide resin bound-III by nucleophilic substitution with (1,4,5,6-tetrahydropyrimidin-2-yl)thiophenol, and hydrolytic cleavage of the product from the resin. II exhibited Ki = 6.9-10.4 nM for the PARP inhibition. II were chemopotentiators of topotecan in A549 cells with PF50 = 2.2.
IT 636573-87-OP, 2-[[[4-(4-hydroxyphenyl)sulfanylmethyl]-4-carboxamido-1H-benzimidazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L3 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (Uses)
 (poly(ADP-ribosyl) polymerase inhibitor; prepn. of
 benzimidazolecarboxamides as poly(ADP-ribosyl) polymerase inhibitors
 for treatment of cancer)
 RN 636573-87-0 CAPLUS
 CN 1H-Benzimidazole-4-carboxamide, 2-[[4-(4-hydroxyphenyl)thio]methyl]- (9CI)
 (CA INDEX NAME)




RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of benzimidazolecarboxamides as poly(ADP-ribosyl)
 polymerase inhibitors for treatment of cancer)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:81836 CAPLUS
 DOCUMENT NUMBER: 139:323345
 TITLE: Preparation of phenoxyacetic acids and
 indanyloxyacetic acids that modulate PPAR activity
 Filzen, Gary Frederick; Trivedi, Bharat Kalidas;
 Geyer, Andrew George; Unangst, Paul Charles; Bratton,
 Larry Don; Auerbach, Bruce Jeffrey
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: PCT Int. Appl., 246 pp.
 CODEN: PIXXD2
 Patent
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084916	A2	20031016	WO 2003-1B1121	20030324
WO 2003084916	A3	20031224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003225158	A1	20031204	US 2003-347749	20030324
US 6875780	B2	20050405		
CA 2481246	AA	20031016	CA 2003-2481246	20030324
AU 2003212578	A1	20031020	AU 2003-212578	20030324
EP 1494989	A2	20050112	EP 2003-708403	20030324
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003009169	A	20050125	BR 2003-9169	20030324
JP 2005521741	T2	20050721	JP 2003-582115	20030324
US 2005113440	A1	20050526	US 2004-979629	20041102
US 6964983	B2	20051115		
US 2005153996	A1	20050714	US 2004-979617	20041102
US 6939875	B2	20050906		
NO 2004004795	A	20041104	NO 2004-4795	20041104
PRIORITY APPLN. INFO.:			US 2002-370508P	P 20020405
			US 2002-386026P	P 20020605
			US 2003-347749	A3 20030122
			WO 2003-1B1121	W 20030324
			US 2003-463641P	P 20030417
OTHER SOURCE(S):		MARPAT 139:323345		
GI				

L3 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; X0, X1 = O, S, CH2, CH=CH, etc.; Ar1, Ar2 = (un)substituted (hetero)aryl, provided that Ar1 is not thiazolyl or oxazolyl; V1 is absent or V1 = (un)saturated (un)substituted hydrocarbon chain having 1-4 atoms; R1, R2 = H, alkyl, alkoxy, etc.; R3, R4 = H, alkyl, alkoxy, etc.; q, r = 0-6] that alter PPAR activity, were prepared and formulated. E.g., a 7-step synthesis of II (starting from 2-hydroxy-4-methoxybenzaldehyde) which showed EC50 of >0-300 nM against PPARα and PPARβ, was given. The invention also discloses pharmaceutically acceptable compns. comprising the compds. I or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia, hypercholesterolemia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal.
 IT 613239-26-2P
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity)
 RN 613239-26-2 CAPLUS
 CN Acetic acid, [4-[[[5-[1,1'-biphenyl]-4-yl]-4,5-dihydro-2-(2-thienyl)-4-oxazolyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



ACCESSION NUMBER: 2003:719305 CAPLUS

DOCUMENT NUMBER: 139:246021

TITLE: Preparation of thiazolymethylthioarylaceta-
tes and related compounds as modulators of peroxisome
proliferator activating receptor (PPAR) activity

INVENTOR(S): Cheng, Xue-min; Erasga, Noe Ouano; Filzen, Gary
Frederick; Geyer, Andrew George; Lee, Chitase;
Trivedi, Bharat Kalidas

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074052	A1	20030912	WO 2003-1B817	20030303
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003207916	A1	20031106	US 2002-324278	20021219
US 6833380	B2	20041221		
CA 2476580	AA	20030912	CA 2003-2476580	20030303
AU 2003207891	A1	20030916	AU 2003-207891	20030303
EP 1485091	A1	20041215	EP 2003-704893	20030303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008221	A	20050104	BR 2003-8221	20030303
JP 2005524665	T2	20050818	JP 2003-572569	20030303
NO 2004004245	A	20041006	NO 2004-4245	20041006
PRIORITY APPLN. INFO.:			US 2002-362400P	P 20020307
			WO 2003-1B817	W 20030303

OTHER SOURCE(S): MARPAT 139:246021
GI




AB Title compds. [I: T = (unsatd.) (substituted) (heteroatom-containing) hydrocarbon chain having 3-6 atoms; W = O, S, CH2, CR4R5, NR3, cycloalkylene, heterocycloalkylene; Y = null, O, CR4R5; Y = CR4R5, null when W = O, S, NR3; and Y = O, null when W = CH2, CR4R5; R1, R2 = H, alkyl, alkoxy, haloalkyl, O(CH2)pCF3, halo, NO2, cyano, OH, SH, CF3, Sopalkyl, Soparyl, (CH2)mOR3, (CH2)mNR6R7, COR3, CO2H, CO2R3, NR6R7; R3 = H, alkyl, alkenyl, alkynyl, aryl; R4, R5 = H, alkyl, alkenyl, alkynyl, aryl, or joined together to form a 4-7 membered ring having 0-3 heteroatoms; R6, R7 = H, alkyl, alkenyl, alkynyl, COalkyl, COaryl, cycloalkyl, CO2alkyl, CO2aryl, SO2alkyl, SO2aryl, or joined together to form a 4-7 member ring having 1-3 heteroatoms; X, X1 = O, S; Ar1 = (substituted) aryl, heteroaryl; m, n = 0-5; p = 0-2), were prepared Thus, Me (8-mercaptopchroman-5-yloxy)acetate (preparation given), 5-chloromethyl-4-methyl-2-(4-trifluoromethylphenyl)thiazole, and Cs2CO3 were stirred in MeCN at 60° for 2.5 h to give 95% Me

[8-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl]chroman-5-yloxy]acetate. The latter was stirred with LiOH.H2O in THF/H2O to give 96% [8-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl]chroman-5-yloxy]acetic acid. The latter in a transient transfection assay using the HepG2 hepatoma cell line showed EC50 = 187 nM for PPARB.

IT 600176-65-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolymethylthioarylaceta-tes and related compds. as modulators of peroxisome proliferator activating receptor (PPAR) activity)

RN 600176-65-6 CAPLUS

CN Acetic acid, [2,3-dihydro-5-methyl-7-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]-4-benzofuranyl]oxy]-, methyl ester (9C1) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 2003:719303 CAPLUS

DOCUMENT NUMBER: 139:246019

TITLE: Preparation of thiazolymethylthiophenylcarb-
oxylates and related compounds as peroxisome
proliferator activated receptor (PPAR) modulators

INVENTOR(S): Cheng, Xue-min; Erasga, Noe Ouano; Filzen, Gary
Frederick; Geyer, Andrew George; Lee, Chitase;
Trivedi, Bharat Kalidas

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074050	A1	20030912	WO 2003-1B708	20030224
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003207924	A1	20031106	US 2002-324148	20021220
CA 2478520	AA	20030912	CA 2003-2478520	20030224
AU 2003206059	A1	20030916	AU 2003-206059	20030224
EP 1482935	A1	20041208	EP 2003-702943	20030224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008277	A	20041228	BR 2003-8277	20030224
JP 2005528348	T2	20050922	JP 2003-572567	20030224
ZA 2004006068	A	20050906	ZA 2004-6068	20040729
NO 2004004242	A	20041006	NO 2004-4242	20041006
PRIORITY APPLN. INFO.:			US 2002-362402P	P 20020307
			WO 2003-1B708	W 20030224

OTHER SOURCE(S): MARPAT 139:246019
GI



AB Title compds. [I; W = O, S, CR5R6, (CH2)p-cycloalkylene, (CH2)p-heterocycloalkylene; X, X1 = O, S; Ar1 = (substituted) aryl, heteroaryl; R1-R4 = H, alkyl, alkoxy, haloalkyl, O(CH2)CF3, halo, NO2, cyano, OH, SH, CF3, SOalkyl, SOaryl, (CH2)mOR7, (CH2)nNR 8R9, COR7, CO2H, CO2R7, NR8R9; R5, R6 = H, alkyl, alkenyl, alkynyl, aryl; R5R6 = 3-7 membered cycloalkyl, cycloalkenyl; R7 = H, alkyl, alkenyl, alkynyl, aryl; R8, R9 = H, alkyl, alkenyl, alkynyl, COalkyl, COaryl, cycloalkyl, CO2alkyl, CO2aryl, SO2alkyl, SO2aryl; R8R9 = 4-7 membered ring having 1-3 heteroatoms; R10, R11 = H, halo, aryl, heteroaryl; m = 0-5; n = 0-5; p = 0-2; with proviso(s), were prepared. Thus, Me (4-mercapto-2,5-dimethylphenoxy)acetate (preparation given), 5-chloromethyl-4-methyl-2-(4-trifluoromethylphenyl)thiazole (preparation given), and Cs2CO3 were stirred 2 h in MeCN to give Me [2,5-dimethyl-4-(4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl)phenoxy]acetate. This was stirred with LiOH in THF/H2O for 1 h to give [2,5-dimethyl-4-(4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfanyl)phenoxy]acetic acid.

I gave a 61-123 mg/dL increase in HDL in mice.

IT 600134-45-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of thiazolymethylthiophenylcarboxylates and related compds. as peroxisome proliferator activated receptor (PPAR) modulators)


RN 600134-45-0 CAPLUS

CN Acetic acid, [5-(acetylamino)-2-methyl-4-[[[4-methyl-2-(4-trifluoromethylphenyl)-5-thiazolyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2003:696736 CAPLUS
DOCUMENT NUMBER: 139:230769
TITLE: Preparation of (aryalkyl)thiazoles and oxazoles as peroxisome proliferator activated receptor modulators for treating diabetes mellitus and atherosclerosis
INVENTOR(S): Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: FIKXKD
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072102	A1	20030904	WO 2003-US2680	20030213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GM, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003214932	A1	20030909	AU 2003-214932	20030213
EP 1480642	A1	20041201	EP 2003-710780	20030213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005528346	T2	20050922	JP 2003-570848	20030213
PRIORITY APPLN. INFO.:			US 2002-359807P	P 20020225
			WO 2003-US2680	W 20030213


OTHER SOURCE(S): MARPAT 139:230769
GI



REFERENCE COUNT: 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT



AB Title compds. I [wherein R3 = H or alkoxy; R4 = H or alkyl; R5 = alkyl, alkenyl, or (un)substituted aryl(oxy)alkyl or arylthioalkyl; R6 = CF3, OCF3, (hydroxy)alkyl, alkylcarbamoyl, carboxyalkoxy, or (un)substituted aryloxy, arylthio, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and


R8 = independently H, CF3, or alkyl; R9 and R10 = independently H, alkyl, alkenyl, or alkoxy; T1 = C or N; Q = bond, O, O(CH2)q, or C; q = 1-2; W = O, S, SO2, NHSO2, etc.; X = CnH2m; m = 0-2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or S; A = CO2H, alkynitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or (un)substituted alkyl or arylmethyl; and pharmaceutically acceptable salts thereof] were prepared as peroxisome proliferator activated receptor (PPAR) agonists (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was coupled with 5-chloromethyl-4-phenethyl-2-(4-trifluoromethylphenyl)thiazole in the presence of Cs2CO3 in MeCN to give the (phenylthiomethyl)thiazole (83.5%), which was saponified with LiOH in THF

to provide II. I and their pharmaceutical compns. are useful for the prevention and or treatment of diabetes mellitus and atherosclerosis (no data).

IT 592518-73-5P, [2-Methyl-4-[[[4-phenethyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]methyl]sulfanyl]phenoxy]acetic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of PPAR agonists for treating diabetes mellitus and atherosclerosis)

RN 592518-73-5 CAPLUS

CN Acetic acid, [2-methyl-4-[[[4-(2-phenylethyl)-2-(4-trifluoromethylphenyl)-5-thiazolyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

ACCESSION NUMBER: 2003:696734 CAPLUS

DOCUMENT NUMBER: 139:230768

TITLE: Preparation of (arylalkyl)thiazoles and oxazoles as peroxisome proliferator activated

receptor

modulators for treating diabetes mellitus, syndrome X,

and cardiovascular disease

INVENTOR(S): Conner, Scott Eugene; Knobelsdorf, James Allen;

Mancio, Nathan Bryan; Schkeryantz, Jeffrey Michael;

Shen, Quanrong; Warshawsky, Alan M.; Zhu, Guoxin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072100	A1	20030904	WO 2003-US2679	20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003217274	A1	20030909	AU 2003-217274	20030213
EP 1480640	A1	20041201	EP 2003-713316	20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005107449	A1	20050519	US 2003-505089	20030213
JP 2005529077	T2	20050929	JP 2003-570846	20030213
PRIORITY APPLN. INFO.:				US 2002-359808P P 20020225
				WO 2003-US2679 W 20030213

OTHER SOURCE(S): MARPAT 139:230768
G1



AB Title compds. I [wherein R3, R4, R30, and R40= independently H, alkyl, halo, or alkoxy; R5 = (un)substituted alkyl, alkenyl, aryl(oxy)alkyl, or arylthioalkyl; or when R5 = alkyl, R5 may be combined with W to form a heterocycloalkyl fused to the oxazole or thiazole ring; R6 = trihalomethyl, trihalomethoxy, (hydroxy)alkyl, alkylcarbamoyl, tetramethyldioxaborolanyl, halo, alkanoyl, carboxyalkoxy, (cyclo)alkoxy, tetrahydropyranyloxy, morpholinyl, or (un)substituted aryloxy, arylthio, heterocyclyloxy, pyridinyl, pyrimidinyl, pyrazinyl, or arylalkyl; R7 and R8 = independently H, CF3, or alkyl; R9 = (un)substituted (aryl)alkyl or alkenyl; R10 = H or alkyl; Q = a bond, O, or CH2; T1 = C or N; W = CH2, O,

OCH2, S, SO2, or (un)substituted CONH, NH, or NHCH2; X = C, CH2C, or

CCH2; Y and Z = independently O, N, or S wherein at least 1 of Y and Z = O or

S; A = CO2H, alkylnitrile, CONH2, or (CH2)nCO2R19; n = 0-3; R19 = H or

alkyl; and pharmaceutically acceptable salts thereof) were prepared as peroxisome proliferator activated receptor S (PPARs)

modulators (no data). For example, (4-mercapto-2-methylphenoxy)acetic acid Et ester was condensed with

1-[4-[2-(2-chloro-6-fluorophenyl)ethyl]-2-(4-trifluoromethylphenyl)thiazol-5-yl]ethanol in the presence of PBU3 and 1,1'-(azodicarbonyl)bipiperidine in toluene. Deesterification with LiOH in THF produced II. I and their pharmaceutical compns. are useful for

the prevention and or treatment of diabetes mellitus, syndrome X, and cardiovascular disease (no data).

IT 591775-08-1P, [4-[[[(1S)-1-[4-ethyl-2-(4-(trifluoromethylphenyl)oxazol-5-yl)ethyl]sulfonyl]-2-methylphenoxy]acetic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(PPAR modulator; preparation of PPAR modulators for treating

diabetes mellitus, syndrome X, and cardiovascular disease)

RN 591775-08-1 CAPLUS

CN Acetic acid, [4-[[[(1S)-1-[4-ethyl-2-(4-(trifluoromethylphenyl)phenyl]-5-oxazolyl]ethyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:888731 CAPLUS

DOCUMENT NUMBER: 137:384743

TITLE:

INVENTOR(S):

Beswick, Paul John; Hamlett, Christopher Charles

Frederick; Patel, Vipulkumar; Sierra, Michael

Lawrence; Ramsden, Nigel Grahame

Glaxo Group Limited, UK

PCT Int. Appl., 141 pp.

CODEN: PIXXD2

Patent

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092590	A1	20021121	WO 2002-GB2152	20020509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446797	A1	20021121	CA 2002-2446797	20020509
EP 1392674	A1	20040303	EP 2002-722506	20020509
EP 1392674	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1507442	A	20040623	CN 2002-809694	20020509
BR 2002009468	A	20040803	BR 2002-9468	20020509
JP 2004534035	T2	20041111	JP 2002-589475	20020509
AT 301649	E	20050815	AT 2002-722506	20020509
ZA 2003008352	A	20050127	ZA 2003-8352	20031027
NO 2003004986	A	20031110	NO 2003-4986	20031110
US 2004157890	A1	20040812	US 2004-476194	20040323
PRIORITY APPLN. INFO.:			GB 2001-11523	A 20010511
			WO 2002-GB2152	W 20020509


OTHER SOURCE(S):

MARPAT 137:384743

GI

L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS ON STN

(Continued)





REFERENCE COUNT: 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB The title compds. [I; X1 = O, S, NH, NMe, alkyl; R1, R2 = H, alkyl; R3-R5 = H, Me, OMe, CF3, halo; m = 0-3; X2 = (CR1OR11)n, O, S, OCH2; n = 1-2; R6, R7, R10, R11 = H, F, alkyl, etc.; one of Y and Z = CH, the other = S, O with the proviso that Y cannot be substituted and Z can only be substituted when it is carbon; R8 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3) with the provision that when R3 = pyridyl, the N is unsubstituted; R9 = alkyl, CF3, CH2D (D = N-substituted piperazino, furyl, piperidino, etc.); R26, R27 = H, alkyl; or R26 and R27, together with the carbon atom to which they are bonded form a 3-5 membered

cycloalkyl ring) and their pharmaceutically acceptable salts, useful for the treatment of a hPPAR mediated disease or condition such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, inflammation and anorexia nervosa, were prepared. Thus, coupling [5-(4-(trifluoromethyl)phenyl)-3-furyl]methanol with Et (4-mercapto-2-methylphenoxy)acetate followed by hydrolysis of the resulting ester afforded the acid II.

IT R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of furan and thiophene derivs. that activate human peroxisome proliferator activated receptors)

RN 476155-07-4 CAPLUS

CN Acetic acid, [2-methyl-4-[[[2-[(1H-1,2,4-triazol-3-ylthio)methyl]-5-[4-(trifluoromethyl)phenyl]-3-furanyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:575057 CAPLUS

DOCUMENT NUMBER: 137:140514

TITLE:

INVENTOR(S):

Banker, Pierrette; Cadilla, Rodolfo; Lambert, Millard

Hurst, III; Rafferty, Stephen William; Sternbach, Daniel David; Sznajdman, Marcos Luis

Glaxo Group Limited, UK

PCT Int. Appl., 138 pp.

CODEN: PIXXD2

Patent

English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059098	A1	20020801	WO 2001-US51056	20011219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1349843	A1	20031008	EP 2001-994514	20011219
EP 1349843	B1	20050420		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520377	T2	20040708	JP 2002-559400	20011219
AT 293611	E	20050515	AT 2001-994514	20011219
PT 1349843	T	20050930	PT 2001-994514	20011219
ES 2240558	T3	20051016	ES 2001-1994514	20011219
US 2004072838	A1	20040415	US 2003-451295	20031031
PRIORITY APPLN. INFO.:			GB 2000-31103	A 20001220
			WO 2001-US51056	W 20011219

OTHER SOURCE(S):


MARPAT 137:140514

GI




AB The title compds. [I; R1, R2 = H, alkyl; X2 = O, S, CH2; R3-R5 = H, alkyl, OMe, CF3, OCF3, CN, allyl, halo; Y = S, O; R25 = Me, OMe, CF3, halo; Y = O-S; R26 = substituted piperazino, piperidino, morpholino, etc.] which activate human peroxisome proliferator activated receptors (hPPARs) and are useful for the treatment of associated disorders such as cardiovascular disease and hypercholesterolemia, were prepared. Thus, reacting 4-(2-([4-(4-methoxyphenyl)-1-piperazinyl]methyl)-2-(4-(trifluoromethyl)phenyl)-1,3-thiazol-5-yl)ethyl)-2-methylphenol (preparation given) with 2-trichloromethyl-2-propanol in the presence of NaOH pellets in acetone afforded 40% II. All exemplified compds. I were agonists of at least one hPPAR subtype (no data given).


IT 444612-04-8P 444612-47-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazole and oxazole derivs. as activators of human peroxisome proliferator activated receptors)
 RN 444612-04-8 CAPLUS
 CN Acetic acid, [4-[[[4-([4-(2-methoxyphenyl)-1-piperazinyl]methyl)-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 444612-47-9 CAPLUS
 CN Acetic acid, [2-methyl-4-[[[4-([4-(trifluoromethoxy)phenyl]methyl)-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




IT 444613-54-1P 444614-10-2P 444614-96-4P
 444613-32-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiazole and oxazole derivs. as activators of human peroxisome proliferator activated receptors)
 RN 444613-54-1 CAPLUS
 CN Acetic acid, [4-[[[4-(hydroxymethyl)-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]methyl]thio]-2-(1-methylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 444614-10-2 CAPLUS
 CN Propanoic acid, 2-[4-[[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 444614-96-4 CAPLUS
 CN Propanoic acid, 2-[4-[[[4-(2,4-dimethoxyphenyl)-1-piperazinyl]methyl]-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]methyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 444615-32-1 CAPLUS
 CN Propanoic acid, 2-[2-methyl-4-[[[4-([4-(2-methyl-1-oxopropyl)-1-piperazinyl]methyl)-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]methyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:241265 CAPLUS
DOCUMENT NUMBER: 132:279549
TITLE: Preparation of cyclic hexapeptides as antifungal and antipneumocystic agents
INVENTOR(S): Wang, Wei-Bo; Li, Qun; Haavold, Lisa A.; Chen, Hui-Ju;

PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIKXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020441	A2	20000413	WO 1999-US22844	19991001
WO 2000020441	A3	20001123		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9964084	A1	20000426	AU 1999-64084	19991001
PRIORITY APPLN. INFO.:			US 1998-166307	A 19981005
			WO 1999-US22844	W 19991001

OTHER SOURCE(S): MARPAT 132:279549
G1

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Cyclic hexapeptides I [R1, R2 = independently H, OH, alkyl, alkoxy, nitro, azido, hydrazinyl, NR12R13; R12, R13 = independently H, alkyl, arylalkyl, guanidiny, etc.; R3, R6 = independently H, alkyl, arylalkyl, alkoxy, amino- or hydroxy alkyl, di- and trialkylaminoalkyl, aminoalkoxy, etc.; R4, R5 = independently H, alkyl, arylalkyl, amino-, hydroxy-, or carboxyalkyl, etc.; or R4 and R5 form (CH2)1CHR14CHR15; 1 = 1-2; R14, R15 = independently R1, R2 or halogen; R7 = alkyl, alkanoyl, aryl, aroyl, alkyloxy-, alkenyloxy-, or aryloxy carbonyl, COR16, CO2R16, CONR16R17, etc.; R16 = aryl, arylalkyl, arylalkoxy, arylalkenyl, aryl-aryl, aryl-hetero-aryl, etc.; R17 = H, alkyl, alkoxy; R8, R9, R10 = independently H, OH, NH2, carboxy; R11 = XR18, YR19; R18 = H, OH, halogen, alkyl, aminoalkyl, nitro, di- and trialkylamino, alkylcarbonyl, etc.; R19 = H, NH2, alkyl, aminoalkyl, alkylcarbonyl, etc.; W = O, S, SO, SO2, NH, N-alkyl, and (CH2)mR21; m = 0-2; R21 = absent, COR22, CONR22, CO2R22; R22

L3 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

—NH2

PAGE 2-A




L3 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
= H, alkyl; X = absent, CO, CH2, NH, CONH, PO2, etc.; Y = O, PO3; Z, Z', Z'' = independently CH, N (with previous) (stereochem. not shown) or their pharmaceutically acceptable salts, esters, and prodrugs were prep'd. as antifungal and antipneumocystic agents. Comps. of formula I were prep'd. by synthesis of the linear lipohexapeptide using std. solid-phase or soln. phase methods, followed by cyclization. They exhibit in vitro activity as antifungal agents against a variety of fungal organisms and inhibit (1,3)-B-glucan synthase. For example, comp'd. 11 (A = CO(p-C6H4)3O(CH2)4CH3) in vitro showed min. inhibitory fungicidal concns. of 50.1 and 0.2 µg/ml against Candida albicans ATCC 10231 and ATCC 38247, resp.

IT 263846-37-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of cyclic hexapeptides as antifungal and antipneumocystic agents)

RN 263846-37-3 CAPLUS
CN L-Proline,
N2-[4-{4-(4-(octyloxy)phenyl)-1-piperazinyl}benzoyl]-L-ornithyl-L-threonyl-L-prolyl-S-(4-hydroxyphenyl)-L-cysteinyl-L-ornithyl-L-amino-, (6-1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L3 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:711820 CAPLUS
DOCUMENT NUMBER: 121:311820
TITLE: Silver halide color photographic material containing pyrazolotriazole magenta coupler
INVENTOR(S): Kato, Eisaku; Ooya, Hidenobu; Suzuki, Takashi
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKOXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06175312	A2	19940624	JP 1992-325681	19921204
PRIORITY APPLN. INFO.:			JP 1992-325681	19921204

G1




AB The material contains pyrazolotriazole magenta coupler I (R1 = substituent; R2-3 = H, alkyl; R4 alkyl, aryl, NR5R6; R5-6 = H, substituent; X = leaving group in reaction with oxidized developer; n = 0-2) in a Ag halide emulsion layer. The material shows good color reproducibility even when pH of the developer is changed.

IT 159115-73-8
RL: TEM (Technical or engineered material use); USES (Uses) (photog. magenta coupler)

RN 159115-73-8 CAPLUS


CN 2,4-Imidazolidinedione, 3-[3-[1-[(4-hydroxyphenyl)sulfonyl]-2-methylpropyl]-6-pentadecyl-1H-pyrazolo[5,1-c]-1,2,4-triazol-7-yl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1993:495328 CAPLUS
 DOCUMENT NUMBER: 119:95328
 TITLE: Indoles as inhibitors of HIV reverse transcriptase
 INVENTOR(S): Williams, Theresa M.; Ciccarone, Terrence M.; Saari, Walfred S.; Wai, John S.; Greenlee, William J.; Balani, Suresh K.; Goldman, Mark E.; Theoharides, Anthony D.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Eur. Pat. Appl., 59 pp.
 DOCUMENT TYPE: CODEN: EPXXDW
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 530907	A1	19930310	EP 1992-202628	19920829
WO 9305020	A1	19930318	WO 1992-US7219	19920826
EP 678508	A1	19951025	EP 1995-201691	19920829
CA 2077283	AA	19930307	CA 1992-2077283	19920901
AU 9222162	A1	19930311	AU 1992-22162	19920904
AU 656615	B2	19950209		
ZA 9206708	A	19930428	ZA 1992-6708	19920904
JP 05208910	A2	19930820	JP 1992-280417	19920907
US 2568161	B2	19970108		
US 5527819	A	19960618	US 1995-488957	19950607
PRIORITY APPLN. INFO.:			US 1991-756013	A 19910906
			US 1992-832260	A 19920207
			US 1992-866765	A 19920409
			EP 1992-202628	A3 19920829
			US 1993-21925	B1 19930224
			US 1994-274101	B1 19940711

OTHER SOURCE(S): MARPAT 119:95328
 GI



AB Many indole-2-carboxamides and analogs thereof are claimed. These compds. are HIV reverse transcriptase inhibitors and claimed for the treatment of AIDS and ARC. The biol. activity of these compds. was not reported. Such

L3 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 a compd. is for example 5-chloro-3-(phenylsulfonyl)-1H-indole-2-carboxamide (I).
 IT 148900-32-7p
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as HIV reverse transcriptase inhibitor)
 RN 148900-32-7 CAPLUS
 CN 1H-Indole, 2-[[[4-methoxyphenyl)sulfinyl)methyl]-3-(phenylthio)- (9CI)
 (CA INDEX NAME)



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	74.87	75.52
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-10.50	-10.50

STN INTERNATIONAL LOGOFF AT 07:49:41 ON 16 FEB 2006